Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 2/20 | 0.37 |
| ▸ | GNAI3 | P08754 | 5/20 | 0.35 |
| ▸ | GNAO1 | P09471 | 5/20 | 0.35 |
| ▸ | GNAI1 | P63096 | 5/20 | 0.35 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.35 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL771054 | 0.94 | LMNA (0.39) | LMNATDP1CHRM1HTTGNAI3 | |
| SCHEMBL770946 | 0.90 | CHRM1 (0.39) | LMNATDP1CHRM1HTTGNAI3 | |
| SCHEMBL771290 | 0.87 | LMNA (0.41) | LMNATDP1CHRM1GNAI3GNAO1 | |
| SCHEMBL770942 | 0.84 | GNAI3 (0.49) | TDP1GNAI3GNAO1GNAI1SIGMAR1 | |
| SCHEMBL802579 | 0.83 | ALDH1A1 (0.40) | LMNACHRM1HTTSIGMAR1HSD11B1 | |
| SCHEMBL771035 | 0.82 | CHRM1 (0.40) | LMNACHRM1HTTHSD11B1 | |
| SCHEMBL769722 | 0.80 | NPC1 (0.46) | — | |
| SCHEMBL771425 | 0.80 | NPSR1 (0.40) | TDP1SIGMAR1 | |
| SCHEMBL770719 | 0.78 | EPHX2 (0.46) | LMNACHRM1HSD11B1 | |
| SCHEMBL771296 | 0.78 | GNAI3 (0.47) | TDP1GNAI3GNAO1GNAI1SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130303522-A1 | INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 | LABORATORIOS SALVAT, S.A. (ES) | 2013-11-14 | — | — | US | disclosed |
| US-20120071466-A1 | INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 | LABORATORIOS SALVAT, S.A. (ES) | 2012-03-22 | — | — | US | disclosed |
| US-20120071466-A1 | INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 | LABORATORIOS SALVAT, S.A. (ES) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130303522-A1 | INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 | HSD11B1, HSD17B1, HSD11B2 | LMNA 3155/4885TDP1 135/4885CHRM1 3030/4885 |
| US-20120071466-A1 | INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 | HSD11B1, HSD17B1, HSD11B2 | LMNA 3116/4885TDP1 134/4885CHRM1 3021/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.